{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023839","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.576903+00:00","generated_at":"2026-06-22T01:25:57.817893+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"4D Molecular Q3 revenue $0.5M, net loss $25.7M; cash $239M covers into H1 2025; 4D-710 CF data positive","bullets":["Cash, cash equivalents and marketable securities totaled $239M; runway into first half of 2025.","Revenue $0.5M (down from $1.4M), net loss $25.7M vs $22.2M, R&D $18.9M.","Interim Phase 1/2 data for 4D-710 CF: no drug-related adverse events, widespread transgene expression in all lung samples.","Clinical progress highlighted across 4D-150, 4D-310, and 4D-710 programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023839","json":"https://secwatch.observer/filing/0000950170-22-023839.json","markdown":"https://secwatch.observer/filing/0000950170-22-023839.md","text":"https://secwatch.observer/filing/0000950170-22-023839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000095017022023839/0000950170-22-023839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000095017022023839/fdmt-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:25:57.817893+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89dcc09bb7f6a28a34f852ac5189a87e24d2863c","claim":"4D Molecular Therapeutics, Inc. reported the quarter ended September 30, 2022 results: revenue $0.5 million, net income $25.7 million.","evidence_excerpt":"Revenue: Total revenue for the quarter ended September 30, 2022, was $0.5 million, as compared to $1.4 million for the quarter ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017022023839/0000950170-22-023839-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$0.5 million"},{"label":"Net income","value":"$25.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}